Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide

Amgen’s update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.

Previous post Here’s what’s driving Friday’s stock action in Apple, Coterra and Eli Lilly
Next post Talent war between family offices and Wall Street drives up salaries